Mechanistic Insights Into AXA1125, a Novel Endogenous Metabolic Modulator Composition, Targeting Multiple NASH Drivers

Introduction

• Recent advances in network biology have assisted in unraveling the complex pathophysiological processes underlying nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH) and cirrhosis1
• The close inter-connectivity of the contributory molecular pathways suggests that effective pharmacotherapy may require a coordinated multitargeted approach
• Per this premise, endogenous metabolic modulators (EMMs) have emerged as a core class of signaling agents and metabolic substrates with the potential to simultaneously impact multiple metabolic and fibroinflammatory pathways in NASH1
• EMMs consisting of amino acids are intrinsically fundamental to core NASH pathways2